NSCLC

This study tested a drug called furmonertinib in 24 adults with advanced lung cancer (non-small cell) that has specific EGFR gene changes and has spread to the brain. The goal was to see if the drug can control brain tumors and delay their growth. Participants took the drug and w…

This study tested a combination of two immune-boosting drugs (eftilagimod alpha and pembrolizumab) in 187 people with advanced lung cancer or head/neck cancer that had not responded to prior treatments. The goal was to see if the combination could shrink tumors safely. Participan…

This study tested a new drug called JAB-21822 in 29 adults with advanced solid tumors (like lung or colon cancer) that have a specific KRAS G12C mutation. The goal was to see if the drug is safe and can shrink tumors. Participants took the drug by mouth, alone or with another dru…

This study tested whether giving focused treatments (like heat or freezing) to cancer spots in the body can help control advanced lung cancer that has spread. The approach uses a blood test to find tiny bits of cancer DNA (minimal residual disease) and treats when levels rise. 37…

This phase 3 trial tested a portable device that delivers low-intensity electric fields (TTFields) to the chest in 291 adults with stage 4 non-small cell lung cancer that worsened after initial chemotherapy. Participants received either standard treatments (chemotherapy or immuno…

This study tested a combination of three drugs (afuresertib, sintilimab, and chemotherapy) in 22 adults with solid tumors like lung, cervical, or stomach cancer that had stopped responding to prior immunotherapy. The goal was to find the safest dose and see if the combo could shr…

This study tested whether adding bevacizumab to erlotinib helps people with a specific type of advanced lung cancer (non-small cell lung cancer with EGFR mutations) live longer without their cancer getting worse. About 311 Chinese patients took part. The goal was to see if the co…

This early-stage study tested a new drug called CFT1946 in 89 adults with advanced solid tumors that have a specific BRAF V600 gene change. The goal was to find safe doses and see if the drug, given alone or with other medicines, can shrink tumors. The study focused on safety and…

This study tested whether adding the experimental drug OSI-906 to the standard targeted therapy erlotinib (Tarceva) helps people with advanced non-small cell lung cancer that has a specific EGFR gene mutation. 88 participants who had not received prior chemotherapy were randomly …

This study tested whether a simple, non-invasive breath test can predict if cancer patients will benefit from immunotherapy drugs. Researchers analyzed the breath of 190 adults with lung, melanoma, bladder, kidney, or head and neck cancers to see if unique chemical patterns could…

This study looked at 3,000 people with advanced non-small cell lung cancer to see if a model using CT scans, lung function tests, and blood markers could predict how well immunotherapy combined with chemotherapy works. It also aimed to predict the risk of a serious side effect ca…

This study looked at people with advanced solid tumors (like lung, bladder, or skin cancer) who had been on immunotherapy (PD-1/PD-L1 inhibitors) for one year and whose disease was stable. It randomly assigned them to either stop treatment or continue until their cancer got worse…